The historical rank and industry rank for CASI Pharmaceuticals's FCF Margin % or its related term are showing as below:
FRA:ENM'
s FCF Margin % Range Over the Past 10 Years
Min: -902.03 Med: -103.25 Max: -61.94
Current: -97.63
During the past 13 years, the highest FCF Margin % of CASI Pharmaceuticals was -61.94%. The lowest was -902.03%. And the median was -103.25%.
FRA:ENM's FCF Margin % is ranked worse than 52.27% of 949
companies
in the Biotechnology industry
Industry Median: -82.65
vs FRA:ENM: -97.63
CASI Pharmaceuticals FCF Margin % Related Terms
CASI Pharmaceuticals FCF Margin % Historical Data
* Premium members only.
The historical data trend for CASI Pharmaceuticals's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ENM vs ITRMF, OGEN, AZTR: FCF Margin % Comparison
For the Biotechnology subindustry, CASI Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals (FRA:ENM) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CASI Pharmaceuticals and its competitors. According to the industry distribution chart, CASI Pharmaceuticals ranks #496 out of 949 companies in the Biotechnology industry, placing it in the top 52.3%.
Is CASI Pharmaceuticals' FCF Margin % too high?
CASI Pharmaceuticals' current FCF Margin % is 0.00%. Based on the distribution chart, CASI Pharmaceuticals ranks #496 out of 949 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' FCF Margin % compare to ITRMF and OGEN?
According to the Biotechnology industry distribution chart, CASI Pharmaceuticals ranks #496 out of 949 companies for FCF Margin %. This places CASI Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current FCF Margin % of 0.00%. The stock's GF Value™ is €11.74, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current FCF Margin % is 0.00%. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.74.
Key valuation signals for FRA:ENM:
FCF Margin %: 0.00%
GF Value™: €11.74 vs. price of €1.54 (86.9% below fair value)
No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for FRA:ENM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ENM has been successfully added to your 
